Table 3 Genotype frequencies of MRC1 and IL28B single nucleotide polymorphisms in HCV-2 infected PEG-IFNα-RBV therapy patients with and without SVR in Taiwan Chinese population
From: Association of MRC-1 and IL-28Bwith the treatment outcome of hepatitis C: a case control study
MRC1 | IL28B | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Genotype | SVR (+) | SVR (−) | P | OR (95% CI) | Genotype | SVR(+) | SVR (−) | P | OR (95% CI) |
N (%) | N (%) | N (%) | N (%) | ||||||
( MRC1 ) rs1926736 | ( IL28B ) rs955155 | ||||||||
C/C | 50 (28.1) | 3 (17.6) | 3.23 (0.75, 13.84) | C/C | 154 (86.5) | 12 (70.6) | 1 | ||
C/T | 97 (54.5) | 8 (47.1) | 2.35 (0.76, 7.29) | C/T | 24 (13.5) | 5 (29.4) | 0.08 | 0.37 (0.12-1.16) | |
T/T | 31 (17.4) | 6 (35.3) | 0.2 | 1 | T/T | 0 (0.0) | 0 (0.0) | - | - |
C/C + C/T | 147 (82.6) | 11 (64.7) | 0.07 | 2.59 (0.89, 7.52) | T/T + C/T | 24 (13.5) | 5 (29.4) | 0.08 | 0.37 (0.12-1.16) |
( MRC1 ) rs691005 | ( IL28B ) rs8099917 | ||||||||
C/C | 16 (9.0) | 4 (23.5) | 0.19 (0.04, 0.82) | T/T | 155 (87.1) | 10 (58.8) | 1 | ||
C/T | 76 (42.7) | 9 (53.0) | 0.39 (0.12, 1.33) | T/G | 23 (12.9) | 7 (41.2) | 0.002* | 0.21 (0.07-0.61) | |
T/T | 86 (48.3) | 4 (23.5) | 0.06 | 1 | G/G | 0 (0.0) | 0 (0.0) | - | |
C/C + C/T | 92 (51.7) | 13 (76.5) | 0.05 | 0.33 (0.10, 1.05) | G/G + T/G | 23 (12.9) | 7 (41.2) | 0.002* | 0.21 (0.07-0.61) |
( IL28B ) rs10853728 | |||||||||
C/C | 116 (65.2) | 6 (35.3) | 1 | ||||||
C/G | 62 (34.8) | 11 (64.7) | 0.02* | 0.29 (0.1-0.83) | |||||
G/G | 0 (0.0) | 0 (0.0) | - | - | |||||
G/G + C/G | 62 (34.8) | 11 (64.7) | 0.02* | 0.29 (0.1-0.83) | |||||